ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy
dc.contributor.author | Kostoff, Matthew D. | |
dc.contributor.author | Saseen, Joseph J. | |
dc.contributor.author | Borgelt, Laura M. | |
dc.date.accessioned | 2014-07-21T19:47:27Z | |
dc.date.available | 2014-07-21T19:47:27Z | |
dc.date.issued | 2014-04-28 | |
dc.identifier.citation | Kostoff, Matthew D. et al. (2014). E valuation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy. International Journal of Women's Health 6:423-428. http://dx.doi.org/10.2147/IJWH.S57549 | |
dc.identifier.issn | 1179-1411 | |
dc.identifier.uri | http://hdl.handle.net/1808/14795 | |
dc.description | This is the publisher's version, also available electronically from http://www.dovepress.com/evaluation-of-fracture-risk-and-potential-drug-holidays-for-postmenopa-peer-reviewed-article-IJWH | |
dc.description.abstract | Study objective: To describe characteristics of postmenopausal women on long-term bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, high), and to determine the prevalence of women eligible for a drug holiday. Design: Retrospective electronic health record review. Setting: Eight primary care clinics within a university-based health care system. Patients: A total of 201 postmenopausal women of ages 55–89 years, with osteopenia or osteoporosis, prescribed bisphosphonate therapy for >4 years, between October 10, 2002 and September 9, 2012. Main results: The patients' mean age was 71.4 (±8.2) years; their mean body mass index was 25.3 (±5.6) kg/m2; and 73.1% were white. Seventy-four out of 201 patients (36.8%) were low-risk; 10/201 (5.0%) were mild-risk; 72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) were high-risk. Eighty-one women (40.3%) were eligible for a drug holiday or discontinuation. The estimated drug cost avoided per eligible patient was $574.80. Calcium and/or vitamin D supplementation was documented in 52.7% of women. Conclusion: More than one-third of postmenopausal women taking long-term bisphosphonate therapy had low fracture risk, and over 40% of our patients were eligble for a drug holiday or discontinuation. These data emphasize the need to accurately assess risk and benefit in patients treated with bisphosphonate therapy. | |
dc.publisher | Dove Medical Press | |
dc.subject | postmenopausal osteoporosis | |
dc.subject | Bisphosphonates | |
dc.subject | Drug holiday | |
dc.subject | Fracture | |
dc.title | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy | |
dc.type | Article | |
kusw.kuauthor | Kostoff, Matthew D. | |
kusw.kudepartment | Pharmacy Practice | |
kusw.oastatus | fullparticipation | |
dc.identifier.doi | 10.2147/IJWH.S57549 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Scholarly Works [299]